This marks the latest development for Velys, J&J’s robotic orthopedic surgery system that won its first FDA clearance for total knee surgery in 2021. In June, Velys won FDA clearance for unicompartmental knee arthroplasty.
The medtech giant’s orthopedics unit developed the spine surgery Velys system in collaboration with eCential Robotics. eCential announced FDA 510(k) clearance for this platform last month. The companies designed the Velys active robotic-assisted system (Velys Spine) for planning and instrumenting spinal fusion procedures. Areas include the cervical, thoracolumbar and sacroiliac spine.
MDO Min-Vasive Medtech Series: Join a live interview with a Johnson & Johnson DePuy Synthes engineer about minimally invasive device design
DePuy Synthes said in a news release that the companies aim for the technology to help surgeons tackle their most complex challenges. The dual-use system offers standalone navigation and an active robotics platform for flexibility in approach and planning. Active robotics enables surgical guidance tailored to surgeon preference.
The company said the distinctive features and capabilities of active robotics could “establish a new standard in spine surgical care.”
Velys Spine offers a customizable experience with pathology-specific workflows, aided by offerings like the Velys adaptive tracking technology and Velys trajectory assistance. It joins the DePuy Synthes core spine portfolio of products, the company said.
DePuy Synthes — the largest orthopedic device company in the world — anticipates full commercial availability in the first half of 2025.
“We are shaping the next frontier of orthopaedic innovation with a relentless focus on digital advancements and excellence in the field of surgical robotics and navigation,” said DePuy Synthes Chair Aldo Denti. “Our dedication extends to enhancing patient care through significant strides in spine surgery. This is a major step in growing our Velyx Portfolio and in our commitment to supporting spine surgeons and their patients with advanced tools.”
Meanwhile, competitor Stryker — which has seen a great deal of success with its Mako robotic surgery systems — expects a Mako Spine launch in the second half of 2024, with Mako Shoulder out by the end of 2024.
